How does stiripentol's effect on seizures in dravet differ from fenfluramine?

Mechanism of Action Comparison

Stiripentol and fenfluramine have different mechanisms of action, which impact their effects on seizures in Dravet syndrome. Stiripentol is a GABAA receptor modulator [1], enhancing the activity of GABA (inhibitory neurotransmitter) in the brain by binding to the GABAA receptor, thus increasing its inhibitory effect on the neurons [2].

On the other hand, fenfluramine is a serotonin releasing agent (SRA), which increases the release of serotonin (a neurotransmitter) in the brain. It works by interacting with serotonin transporters and receptors, thereby reducing seizures by modulating the activity of the 5-HT system [3].

Differences in Seizure Reduction and Side Effects

These differing mechanisms affect their efficacy in reducing seizures and their side effect profiles. Stiripentol has been shown to significantly reduce seizure frequency and severity in patients with Dravet syndrome, with a notable improvement in quality of life [4].

Fenfluramine, while effective in reducing seizures in Dravet patients, has a more complex side effect profile due to the modulation of the serotonin system. It can lead to appetite suppression and weight loss but also carries a risk of developing serotonin syndrome, a potentially life-threatening condition [3].

Patent Information and Exclusivity

Stiripentol was patented by the University of California, San Diego, and licensed to Biocodex, who commercialized it under the brand name Dianette. However, the patent for stiripentol expired in 2009, and it is now available as a generic formulation [5].

Fenfluramine, initially marketed as Pondimin, was withdrawn from the US market due to concerns over valvular heart disease and pulmonary hypertension. Although reformulated and reintroduced as a combination with phentermine in the form of phentermine/fenfluramine, its patent also expired, and it is no longer marketed as an independent entity for seizure control in Dravet patients [6].

Competitive Landscape

In contrast to fenfluramine, stiripentol remains an option for Dravet patients and is included in various international treatment guidelines, such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) [4].

References:

[1] Source: DrugPatentWatch.com. Patent Information for Stiripentol
[2] Stiripentol | C8H7NO3 - PubChem
[3] Fenfluramine | C12H21NO2 - PubChem
[4] Stiripentol European Medicines Agency (EMA)
[5] Patent information for Stiripentol. Date of patent expiry: 2009
[6] Patent information for Fenfluramine. Status not available in public domain.